Is there a signifi cant difference between the moderate and severe airfl ow limitation groups regarding the use of short-acting β 2 -agonists?
What are the frequency and percentage of the COPD patients in the severe airfl ow limitation group who are employed in the Eckerblad et al. (2014) study?